AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23142302 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant modified vaccinia Ankara (rMVA) and fowlpox (rFPV) with matched HIV-1 inserts
Number of subjects: 150
Study 23142302 — intervention group
Group type: COMPARATOR
Intervention: Empty vectors (MVA and FPV)
Number of subjects: 150
Study 23142302 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA (up to 5 administrations)
Number of subjects: 150
Study 23142302 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MVA
Number of subjects: 150
Study 19815652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-epirubicin-paclitaxel (PET)
Number of subjects: 200
Study 19815652 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-paclitaxel (ET)
Number of subjects: 200
Study 18570984 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite resin restoration without cuspal coverage
Number of subjects: 41
Study 18570984 — intervention group
Group type: COMPARATOR
Intervention: Direct composite resin restoration with cuspal coverage
Number of subjects: 41
Study 16200842 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 16200842 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 35
Study 11409855 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term ventilation tubes
Number of subjects: 187
Study 11409855 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 187
Study 11367650 — intervention group
Group type: EXPERIMENTAL
Intervention: Huancongdan (HCD) capsule
Number of subjects: 72
Study 11367650 — intervention group
Group type: COMPARATOR
Intervention: Hydergine
Number of subjects: 72
Study 8156307 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/day for 2 weeks, then 11 weeks off etidronate; four cycles total) + Prednisone
Number of subjects: 20
Study 8156307 — intervention group
Group type: COMPARATOR
Intervention: Prednisone only
Number of subjects: 20
Study 8156307 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate + Prednisone
Number of subjects: 20
Study 3045423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus Adriamycin
Number of subjects: 0
Study 3045423 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study 3045423 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CYVADIC chemotherapy (cyclophosphamide, vincristine, Adriamycin, and dacarbazine)
Number of subjects: 0
Study 3045423 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant VAC chemotherapy (vincristine, actinomycin-D, and cyclophosphamide)
Number of subjects: 0
Study 31185942 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.1 mg/kg
Number of subjects: 40
Study 31185942 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0.1 μg/kg
Number of subjects: 40
Study 28407754 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback with peer review
Number of subjects: 197
Study 28407754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 197
Study 26856016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm fluoride as sodium monofluorophosphate (SMFP)/zinc‐based dentifrice
Number of subjects: 86
Study 26856016 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride as sodium monofluorophosphate (SMFP)/zinc‐free dentifrice
Number of subjects: 86
Study 23549409 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated oral supplement of Bifidobacterium infantis 35624
Number of subjects: 117
Study 23549409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 21760569 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 113
Study 19390464 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Optical Access (DOA)
Number of subjects: 186
Study 19390464 — intervention group
Group type: COMPARATOR
Intervention: Closed Veress Needle Approach
Number of subjects: 186
Study 17126655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic patients (oral body temperature <35.8 degrees C)
Number of subjects: 319
Study 17126655 — intervention group
Group type: COMPARATOR
Intervention: Nonhypothermic patients (oral body temperature ≥35.8 degrees C)
Number of subjects: 319
Study 17126655 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 319
Study 17126655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic patients
Number of subjects: 319
Study 15387206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) affiliation composite scale including AA attendance, sum of steps completed, and identifying self as an AA member
Number of subjects: 1506
Study 15387206 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-item AA affiliation scale
Number of subjects: 1506
Study 11314621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (nalbuphine HCl and ketorolac tromethamine)
Number of subjects: 30
Study 11314621 — intervention group
Group type: COMPARATOR
Intervention: Conventional pethidine HCl intramuscular group
Number of subjects: 30
Study 9146938 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical azelastine (0.254 mg per nasal cavity)
Number of subjects: 0
Study 9146938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cetirizine (10 mg)
Number of subjects: 0
Study 9146938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7712967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 89
Study 7712967 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 29249140 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (EG1) - water gymnastics classes with emphasis on lower limb exercises for 12 weeks
Number of subjects: 90
Study 29249140 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (EG2) - conventional hydrogymnastics classes for 12 weeks
Number of subjects: 90
Study 29249140 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no exercise during the 12 weeks
Number of subjects: 90
Study 29231763 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 92
Study 29231763 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 92
Study 29231763 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS (eCH subgroup)
Number of subjects: 92
Study 29231763 — intervention group
Group type: COMPARATOR
Intervention: sham (eCH subgroup)
Number of subjects: 92
Study 29231763 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS (cCH subgroup)
Number of subjects: 92
Study 29231763 — intervention group
Group type: COMPARATOR
Intervention: sham (cCH subgroup)
Number of subjects: 92
Study 27009758 — intervention group
Group type: COMPARATOR
Intervention: 11-cm short sheath (Group A)
Number of subjects: 52
Study 27009758 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-cm long sheath (Group B)
Number of subjects: 52
Study 27009758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 24147933 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX‐101 (1 mg cm(‐2))
Number of subjects: 363
Study 24147933 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX‐101 (2 mg cm(‐2))
Number of subjects: 363
Study 24147933 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX‐101
Number of subjects: 363
Study 24147933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 22571072 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information (short video about practical aspects of the hospital stay, surgical and adjuvant treatment)
Number of subjects: 60
Study 22571072 — intervention group
Group type: COMPARATOR
Intervention: Routine informed consent only
Number of subjects: 60
Study 20154074 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% nitrogen through a 40% venturi mask at a flow rate of 10 L/min for 2 h
Number of subjects: 20
Study 20154074 — intervention group
Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 20
Study 18421054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1401
Study 18421054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1401
Study 16643574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education
Number of subjects: 100
Study 16643574 — intervention group
Group type: COMPARATOR
Intervention: Routine medical management only
Number of subjects: 100
Study 14661284 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients informed about adverse effects of contrast material
Number of subjects: 297
Study 14661284 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninformed patients waiting for i.v. contrast material injection
Number of subjects: 297
Study 14661284 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninformed patients undergoing unenhanced CT examination
Number of subjects: 297
Study 10749632 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous biphasic calcium phosphate ceramic blocks comprising hydroxyapatite and tricalcium phosphate
Number of subjects: 58
Study 10749632 — intervention group
Group type: COMPARATOR
Intervention: Local bone grafts combined with autogenous iliac bone grafts
Number of subjects: 58
Study 8841209 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 2 mg IV
Number of subjects: 96
Study 8841209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1365676 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (100 mg/serving) under forced-choice condition
Number of subjects: 10
Study 1365676 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee under forced-choice condition
Number of subjects: 10
Study 1365676 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee under free-choice condition
Number of subjects: 10
Study 1365676 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee under free-choice condition
Number of subjects: 10
Study 6384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (6 g/m2 given 4 hr before each of the first 3 doses of RT)
Number of subjects: 0
Study 6384434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 0
Study 6384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (6 g/m2)
Number of subjects: 0
Study 31623760 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay with sex-specific thresholds
Number of subjects: 48282
Study 28521541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavaborole topical solution, 5%
Number of subjects: 62
Study 28521541 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 62
Study 26955677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan (TJQ) training
Number of subjects: 60
Study 24842847 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time CPR cycles (120s)
Number of subjects: 54
Study 24842847 — intervention group
Group type: COMPARATOR
Intervention: Shortened CPR cycles (30-45s)
Number of subjects: 54
Study 22389634 — intervention group
Group type: COMPARATOR
Intervention: Clean delivery kit use
Number of subjects: 19754
Study 22389634 — intervention group
Group type: COMPARATOR
Intervention: Individual clean delivery practices (boiled blade and thread, plastic sheet, gloves, hand washing, appropriate cord care)
Number of subjects: 19754
Study 22389634 — intervention group
Group type: COMPARATOR
Intervention: Each additional clean delivery practice used
Number of subjects: 19754
Study 20849498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PNB
Number of subjects: 40
Study 20849498 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based technique (LBT)
Number of subjects: 40
Study 17187609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychological treatment and physiotherapy (Group A)
Number of subjects: 83
Study 17187609 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only (Group B)
Number of subjects: 83
Study 17187609 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated combination of psychological treatment and somatic treatment (Group C)
Number of subjects: 83
Study 15727400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 mcg/kg) plus midazolam (0.02 mg/kg)
Number of subjects: 70
Study 15727400 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.5 mg/kg) plus midazolam (0.02 mg/kg)
Number of subjects: 70
Study 12011785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of dopamine and diltiazem
Number of subjects: 60
Study 12011785 — intervention group
Group type: COMPARATOR
Intervention: Dopamine-only
Number of subjects: 60
Study 12011785 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem-only
Number of subjects: 60
Study 12011785 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 9764096 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational rehabilitation by occupational physicians
Number of subjects: 0
Study 7906331 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolectomy
Number of subjects: 37
Study 7906331 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis (alteplase)
Number of subjects: 37
Study 2527544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg day‐1)
Number of subjects: 23
Study 2527544 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg day‐1)
Number of subjects: 23
Study 12782 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 10
Study 12782 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 10
Study 31197361 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10^7 bmMSCs (cohort 1, n = 5)
Number of subjects: 21
Study 31197361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10^7 bmMSCs (cohort 2, n = 5)
Number of subjects: 21
Study 31197361 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 x 10^7 bmMSCs (cohort 3, n = 5)
Number of subjects: 21
Study 31197361 — intervention group
Group type: EXPERIMENTAL
Intervention: bmMSC therapy
Number of subjects: 21
Study 30507632 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (R-ZES)
Number of subjects: 302
Study 30507632 — intervention group
Group type: COMPARATOR
Intervention: Xience everolimus-eluting stents (EES)
Number of subjects: 302
Study 30507632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both R-ZES and EES
Number of subjects: 302
Study 28087178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (bilateral Five Shu in Spleen Meridian), once daily for 10 consecutive days.
Number of subjects: 123
Study 28087178 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (same acupoints using Park Sham Device), once daily for 10 consecutive days.
Number of subjects: 123
Study 26476417 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course chemoradiotherapy (LC)
Number of subjects: 106
Study 26476417 — intervention group
Group type: COMPARATOR
Intervention: Short course radiotherapy (SC)
Number of subjects: 106
Study 26476417 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 106
Study 26476417 — intervention group
Group type: COMPARATOR
Intervention: Long cue vignettes
Number of subjects: 106
Study 26476417 — intervention group
Group type: COMPARATOR
Intervention: Tumour stage, nodal status, tumour position, circumferential location
Number of subjects: 106
Study 26476417 — intervention group
Group type: COMPARATOR
Intervention: T4 tumour
Number of subjects: 106
Study 23288026 — intervention group
Group type: EXPERIMENTAL
Intervention: Delicate surgery and closure by primary intention (Protocol A)
Number of subjects: 700
Study 23288026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraumatic avulsion and closure by secondary intention (Protocol B)
Number of subjects: 700
Study 21127910 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS)
Number of subjects: 18
Study 21127910 — intervention group
Group type: COMPARATOR
Intervention: Non-lifelike simulator
Number of subjects: 18
Study 21127910 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 18
Study 19308861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified regional anaesthetic block technique (single upper arm tourniquet, single forearm tourniquet)
Number of subjects: 20
Study 19308861 — intervention group
Group type: COMPARATOR
Intervention: Traditional bier block (double upper arm tourniquet)
Number of subjects: 20
Study 19308861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified regional anaesthetic block technique
Number of subjects: 20
Study 19308861 — intervention group
Group type: COMPARATOR
Intervention: Traditional bier block
Number of subjects: 20
Study 17096621 — intervention group
Group type: COMPARATOR
Intervention: Various interventions including counseling, education, self‐medication programs, cues and organizers, and decreasing dosing frequency.
Number of subjects: 57
Study 17096621 — intervention group
Group type: COMPARATOR
Intervention: Decreasing dosing frequency and self‐medication programs.
Number of subjects: 57
Study 14755979 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercises 3‐5 times/week, 45‐60 min. per session, combined with antihypertensive drug therapy (Group B)
Number of subjects: 80
Study 14755979 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drug therapy only (Group C)
Number of subjects: 80
Study 14755979 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercises and antihypertensive therapy (Group B)
Number of subjects: 80
Study 10727313 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg cyclosporine microemulsion daily
Number of subjects: 106
Study 10727313 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg cyclosporine microemulsion daily
Number of subjects: 106
Study 9387716 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese tonics with strengthened nutrients
Number of subjects: 103
Study 1552913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (0.4 g per kilogram per day)
Number of subjects: 150
Study 1552913 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (200 to 250 ml per kilogram of body weight)
Number of subjects: 150
Study 1552913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 150
Study 1552913 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 150
Study 2933999 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate + fentanyl
Number of subjects: 45
Study 2933999 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam + fentanyl
Number of subjects: 45
Study 2933999 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam + fentanyl
Number of subjects: 45
Study 31053142 — intervention group
Group type: COMPARATOR
Intervention: 3 standard doses of HBV vaccination (20 μg at month 0, 1, 6)
Number of subjects: 54
Study 31053142 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 standard doses of HBV vaccination (20 μg at month 0, 1, 2, 6)
Number of subjects: 54
Study 31053142 — intervention group
Group type: COMPARATOR
Intervention: 3 standard doses of HBV vaccination
Number of subjects: 54
Study 31053142 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 standard doses of HBV vaccination
Number of subjects: 54
Study 29748420 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily remote ischaemic conditioning (rIC) for 4 weeks starting on day 3 post P‐PCI
Number of subjects: 73
Study 29748420 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 73
Study 29748420 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily remote ischaemic conditioning (rIC)
Number of subjects: 73
Study 28256813 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-MOR group (3 mg bupivacaine + 50 mcg morphine)
Number of subjects: 66
Study 28256813 — intervention group
Group type: COMPARATOR
Intervention: BUP group (5 mg bupivacaine)
Number of subjects: 66
Study 24732143 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 231
Study 24732143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (SED-time)
Number of subjects: 231
Study 24732143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat indices
Number of subjects: 231
Study 23292847 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity Training (VT)
Number of subjects: 16
Study 23292847 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength Training (ST)
Number of subjects: 16
Study 21680944 — intervention group
Group type: COMPARATOR
Intervention: Conventional invasive weaning
Number of subjects: 208
Study 21680944 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 208
Study 21680944 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 208
Study 17387332 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine replacement therapy transdermal patch
Number of subjects: 720
Study 17387332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 17387332 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD4 VNTR genotype
Number of subjects: 720
Study 17387332 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD4 C-521T genotype
Number of subjects: 720
Study 17268395 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 17268395 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer M3 receptor selective anticholinergics (solifenacin, darifenacin)
Number of subjects: 0
Study 17268395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin patch
Number of subjects: 0
Study 12830340 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg o.d.
Number of subjects: 38
Study 12830340 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg o.d.
Number of subjects: 38
Study 12830340 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril and Amlodipine combination o.d.
Number of subjects: 38
Study 11273913 — intervention group
Group type: COMPARATOR
Intervention: Total-IV anesthesia (TIVA) with propofol and fentanyl
Number of subjects: 50